Detalhe da pesquisa
1.
Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors.
Neurooncol Adv
; 5(1): vdad156, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38130899
2.
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.
bioRxiv
; 2023 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36778419
3.
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Sci Adv
; 9(47): eadg8876, 2023 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38000020
4.
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Clin Cancer Res
; 29(17): 3484-3497, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410426
5.
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
Neuro Oncol
; 25(11): 2044-2057, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246765
6.
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene
; 41(21): 2973-2983, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459782
7.
Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Cancer Res
; 81(3): 747-762, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33203698
8.
Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene
; 41(21): 3037, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534540